Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929538 | 1.00 | KMT2A (0.47) | KMT2AL3MBTL1POLBPKMPTPN1 | |
| SCHEMBL5929569 | 0.83 | KMT2A (0.50) | KMT2AL3MBTL1POLBPKMPTPN1 | |
| SCHEMBL5158141 | 0.83 | KMT2A (0.50) | KMT2AL3MBTL1POLBPKMPTPN1 | |
| SCHEMBL6778631 | 0.83 | ALDH1A1 (0.44) | KMT2AL3MBTL1POLBPKMPTPN1 | |
| Hydrochloric Acid SCHEMBL6777270 | 0.81 | ALDH1A1 (0.43) | KMT2AL3MBTL1POLBPKMPTPN1 | |
| SCHEMBL9499104 | 0.81 | CYP4F2 (0.45) | KMT2AL3MBTL1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL985943 | 0.78 | KMT2A (0.56) | KMT2AL3MBTL1POLBPKMPTPN1 | |
| SCHEMBL11306306 | 0.78 | ALDH1A1 (0.42) | KMT2AL3MBTL1POLBPKMPTPN1 | |
| SCHEMBL12897248 | 0.78 | KMT2A (0.55) | KMT2AL3MBTL1POLBPKMPTPN1 | |
| SCHEMBL27813691 | 0.77 | KMT2A (0.59) | KMT2AL3MBTL1POLBPKMPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| EP-1405917-B1 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | SALTIGO GMBH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-1471056-B1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-7662974-B2 | reduction of carboxylic acid ester using metal hydride complexes and metal halides to form compounds such as ethyl (3S)-3-hydroxy-3-{6-[(methylamino)carbonyl]-2-naphthyl}-3-(1-trityl-1H-imidazol-4-yl)propanoate, used as lyase enzyme inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7662974-B2 | reduction of carboxylic acid ester using metal hydride complexes and metal halides to form compounds such as ethyl (3S)-3-hydroxy-3-{6-[(methylamino)carbonyl]-2-naphthyl}-3-(1-trityl-1H-imidazol-4-yl)propanoate, used as lyase enzyme inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7662974-B2 | reduction of carboxylic acid ester using metal hydride complexes and metal halides to form compounds such as ethyl (3S)-3-hydroxy-3-{6-[(methylamino)carbonyl]-2-naphthyl}-3-(1-trityl-1H-imidazol-4-yl)propanoate, used as lyase enzyme inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7553970-B2 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553970-B2 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2009-06-30 | — | — | US | disclosed |
| US-20060264641-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | BERENDES FRANK | 2006-11-23 | — | — | US | disclosed |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471056-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | KMT2A 1391/4885L3MBTL1 3835/4885POLB 3485/4885 |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | CYP17A1, HSD17B7, HSD17B1 | KMT2A 1373/4885L3MBTL1 3843/4885POLB 3470/4885 |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | KMT2A 1391/4885L3MBTL1 3835/4885POLB 3485/4885 |
| US-20060264641-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | HPD, HAAO, GRHPR | KMT2A 1997/4885L3MBTL1 4641/4885POLB 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.